Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers

The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.